Evidence map›Paper›PMID 39687135›Full record

ArticleHeliyon2024

Intelligent management and legal regulation of enterprise green supply chain by fuzzy comprehensive evaluation.

Junfeng Wang

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Junfeng WangSchool of Law, Liaoning Normal University, Dalian, 116083, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to evaluate the risk levels of intelligent management in Green Supply Chain Management (GSCM) through the application of the Fuzzy Comprehensive Evaluation (FCE) model. It begins by outlining the structure of the green supply chain (GSC), encompassing various components such as suppliers, manufacturers, and distributors, while incorporating considerations of environmental and sustainability factors. Data is collected from Company Y through a questionnaire survey, and the FCE model is employed to assess the risk levels of intelligent management within GSCM. The study identifies that Company Y faces high-risk factors in supply chain management, including customer demand fluctuations, inadequate supplier capacity, and reliance on exclusive suppliers, with a risk rating of 4. Additionally, moderate-risk factors, such as partnerships, policies, cash flow, technological capabilities, and internal production management, were rated at a risk level of 3. Based on the risk assessment results, the study proposes several recommendations for improvement. These include reinforcing the enforcement of environmental policies, establishing mechanisms for supply chain information transparency, and promoting clean production technologies. These recommendations are intended to assist the company in better adhering to environmental regulations and fostering sustainable supply chain development. The study's innovation lies in the successful integration of the FCE model into the supply chain risk assessment framework, effectively combining subjective evaluations with objective data to improve the accuracy of the assessment. The findings provide scientific evidence for companies to manage risks and formulate strategies, while also offering new insights into the multidimensional nature of supply chain risks, encompassing social, economic, environmental, and technological dimensions.

Indexed as

Fuzzy comprehensive evaluationGreen supply chainLegal supervision legal regulationSupply chain intelligent management risk

Identifiers

PMID39687135
PMCPMC11648754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.